Advancements in Treating Unresectable Stage III Non-Small Cell Lung Cancer
Author Information
Author(s): Narra Lakshmi Rekha, Kumar Ritesh, Deek Matthew P., Jabbour Salma K.
Primary Institution: Department of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA
Hypothesis
How can the management of unresectable Stage III non-small-cell lung cancer be improved through advancements in treatment strategies?
Conclusion
Integrating modern radiation techniques, systemic therapies, and immunotherapy has significantly improved outcomes for patients with unresectable Stage III non-small-cell lung cancer.
Supporting Evidence
- Concurrent chemoradiotherapy remains the cornerstone of treatment despite modest survival outcomes.
- Immunotherapy with PD-L1 inhibitors has shown improved survival rates in patients.
- Emerging biomarkers like circulating tumor DNA offer potential for personalized therapy.
Takeaway
Doctors are finding better ways to treat a type of lung cancer that can't be removed with surgery, using new technologies and medicines to help patients live longer and feel better.
Methodology
This narrative review explores current management strategies and advancements in treatment for unresectable Stage III NSCLC.
Limitations
The review is based on existing literature and does not present original research data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website